MedTrace Logo

Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes

NCT02526615 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2015-08-18

No results posted yet for this study

Summary

The objectives of this study are to compare the effects of rosiglitazone and metformin on insulin stimulated glucose uptake in subjects with type 2 diabetes. Whole body, and skeletal muscle, heart and adipose tissue insulin stimulated glucose uptake is measured during euglycemic hyperinsulinemic clamp and positron-emission tomography scanning before and 26 weeks after treatment in 48 newly diagnosed subjects with type 2 diabetes. Subjects will be randomized to receive either rosiglitazone or metformin or placebo, according to a simple randomization procedure with double blinding.

Conditions

Interventions

DRUG

Rosiglitazone

Patients received either placebo, metformin or rosiglitazone

DRUG

Metformin

Patients received either placebo, metformin or rosiglitazone

DRUG

Placebo

Patients received either placebo, metformin or rosiglitazone

Sponsors & Collaborators

  • SmithKline Beecham

    collaborator INDUSTRY

  • Turku University Hospital

    lead OTHER_GOV

Principal Investigators

  • Pirjo Nuutila, MD, PhD · Turku University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-10-31
Primary Completion
2001-12-31
Completion
2001-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02526615 on ClinicalTrials.gov